BR112023023558A2 - Anticorpos anti-tmprss6 e usos dos mesmos - Google Patents
Anticorpos anti-tmprss6 e usos dos mesmosInfo
- Publication number
- BR112023023558A2 BR112023023558A2 BR112023023558A BR112023023558A BR112023023558A2 BR 112023023558 A2 BR112023023558 A2 BR 112023023558A2 BR 112023023558 A BR112023023558 A BR 112023023558A BR 112023023558 A BR112023023558 A BR 112023023558A BR 112023023558 A2 BR112023023558 A2 BR 112023023558A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- tmprss6
- bind
- disorder
- humans
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187150P | 2021-05-11 | 2021-05-11 | |
| PCT/US2022/028595 WO2022240877A1 (en) | 2021-05-11 | 2022-05-10 | Anti-tmprss6 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023023558A2 true BR112023023558A2 (pt) | 2024-03-12 |
Family
ID=81927373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023023558A BR112023023558A2 (pt) | 2021-05-11 | 2022-05-10 | Anticorpos anti-tmprss6 e usos dos mesmos |
Country Status (14)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022240877A1 (en) | 2021-05-11 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss6 antibodies and uses thereof |
| CN120936629A (zh) * | 2023-04-04 | 2025-11-11 | 迪斯克医药公司 | 抗tmprss6抗体及其用途 |
| WO2025245434A1 (en) * | 2024-05-24 | 2025-11-27 | Disc Medicine, Inc. | Compositions and methods for treating myelodysplastic syndromes (mds) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| GB0916576D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AU2016302768B2 (en) | 2015-07-31 | 2019-08-22 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
| EP4065607A1 (en) | 2019-11-29 | 2022-10-05 | Kymab Limited | Treatment for physiological iron overload |
| AU2021251087A1 (en) | 2020-04-07 | 2022-12-01 | Mabwell Therapeutics Inc. | Anti-TMPRSS6 antibodies and uses thereof |
| WO2022240877A1 (en) | 2021-05-11 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss6 antibodies and uses thereof |
-
2022
- 2022-05-10 WO PCT/US2022/028595 patent/WO2022240877A1/en not_active Ceased
- 2022-05-10 JP JP2023569823A patent/JP2024517931A/ja active Pending
- 2022-05-10 CA CA3218455A patent/CA3218455A1/en active Pending
- 2022-05-10 US US17/741,234 patent/US12448435B2/en active Active
- 2022-05-10 BR BR112023023558A patent/BR112023023558A2/pt unknown
- 2022-05-10 MA MA63064A patent/MA63064B1/fr unknown
- 2022-05-10 MX MX2023013248A patent/MX2023013248A/es unknown
- 2022-05-10 CN CN202280047837.4A patent/CN117730099A/zh active Pending
- 2022-05-10 EP EP22727583.1A patent/EP4337695A1/en active Pending
- 2022-05-10 KR KR1020237042253A patent/KR20240005894A/ko active Pending
- 2022-05-10 AU AU2022274888A patent/AU2022274888A1/en active Pending
- 2022-05-10 IL IL308375A patent/IL308375A/en unknown
-
2023
- 2023-11-08 CL CL2023003331A patent/CL2023003331A1/es unknown
- 2023-12-04 CO CONC2023/0016777A patent/CO2023016777A2/es unknown
-
2025
- 2025-09-09 US US19/323,318 patent/US20260098084A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260098084A1 (en) | 2026-04-09 |
| CA3218455A1 (en) | 2022-11-17 |
| US12448435B2 (en) | 2025-10-21 |
| CO2023016777A2 (es) | 2023-12-11 |
| JP2024517931A (ja) | 2024-04-23 |
| CN117730099A (zh) | 2024-03-19 |
| EP4337695A1 (en) | 2024-03-20 |
| MA63064A1 (fr) | 2024-02-29 |
| MA63064B1 (fr) | 2025-02-28 |
| CL2023003331A1 (es) | 2024-06-07 |
| MX2023013248A (es) | 2024-01-29 |
| US20220411487A1 (en) | 2022-12-29 |
| KR20240005894A (ko) | 2024-01-12 |
| AU2022274888A1 (en) | 2023-12-07 |
| IL308375A (en) | 2024-01-01 |
| WO2022240877A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022017930A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
| BR112022023088A2 (pt) | Anticorpos contra sars-cov-2 e métodos de seleção e uso dos mesmos | |
| BR112022014623A2 (pt) | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos | |
| BR112021016398A2 (pt) | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer | |
| CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
| BR112022001368A2 (pt) | Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos | |
| BR112023016574A2 (pt) | Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão | |
| BR112022000216A2 (pt) | Anticorpos direcionados a dll3 e usos dos mesmos | |
| BR112019022515A2 (pt) | Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos | |
| BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
| BR112023016580A2 (pt) | Anticorpos anti-tcr delta variáveis 1 | |
| BR112022012474A2 (pt) | Anticorpo anti-lilrb1, fragmento de ligação ao antígeno do mesmo, composição farmacêutica que compreende os mesmos, uso do dito anticorpo para tratar ou prevenir um câncer, método de preparar o dito anticorpo, molécula de ácido nucleico e vetor e célula recombinantes. | |
| BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
| CL2024000378A1 (es) | Anticuerpos anti-npr1 y usos de los mismos. | |
| JOP20190093A1 (ar) | أجسام مضادة لـ il-33 واستخداماتها | |
| CL2023003331A1 (es) | Anticuerpos anti-tmprs66 y usos de los mismos. | |
| BR112022003635A2 (pt) | Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso | |
| CO2023001559A2 (es) | Anticuerpos fgfr3 y métodos de uso | |
| BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
| BR112022021065A2 (pt) | Anticorpos terapêuticos de musk | |
| CR20220660A (es) | Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2 | |
| WO2020076789A3 (en) | Combinations of anti-staphylococcus aureus antibodies | |
| BR112022011570A2 (pt) | Anticorpos anti-mertk e métodos de uso dos mesmos | |
| BR112022024149A2 (pt) | Anticorpos antiglicoproteína spike de anti-sars-cov-2 e fragmentos de ligação a antígeno | |
| EA201992626A1 (ru) | Способы и композиции для лечения аллергических заболеваний глаз |